

# Nozomu Fuse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5804650/publications.pdf>

Version: 2024-02-01

18  
papers

420  
citations

933447

10  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

769  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 161-172.	5.3	18
2	Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. <i>Gastric Cancer</i> , 2013, 16, 324-328.	5.3	15
3	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	6.3	78
4	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	2.8	136
5	Early Clinical Outcomes of Anal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy with 5-Fluorouracil Plus Mitomycin C in Japanese Patients: Experience at a Single Institution. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 861-864.	1.3	1
6	Induction Chemotherapy with Docetaxel, Cisplatin and S-1 Followed by Proton Beam Therapy Concurrent with Cisplatin in Patients with T4b Nasal and Sinonasal Malignancies. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 691-696.	1.3	22
7	Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 787-793.	1.3	19
8	Efficacy of Concurrent Chemoradiotherapy as a Palliative Treatment in Stage IVB Esophageal Cancer Patients with Dysphagia. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 964-972.	1.3	36
9	Genetic Variation and Haplotype Structures of the Glutathione S-transferase Genes GSTA1 and GSTA2 in Japanese Colorectal Cancer Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 646-658.	2.2	7
10	Genetic Polymorphisms of FCGRT Encoding FcRn in a Japanese Population and Their Functional Analysis. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 578-587.	2.2	19
11	Therapeutic Significance of a D-dimer Cut-off Level of $\geq 3 \text{ } \mu\text{g/ml}$ in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 933-937.	1.3	7
12	Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2010, 30, 243-249.	2.2	5
13	Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 225-230.	1.3	9
14	Genetic Polymorphisms of Copper-and Platinum Drug-efflux Transporters ATP7A and ATP7B in Japanese Cancer Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 565-574.	2.2	13
15	Future perspectives of chemotherapy for advanced gastric cancer. <i>Gastric Cancer</i> , 2009, 12, 60-66.	5.3	5
16	Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 144-149.	2.2	12
17	Feasibility of Oxaliplatin and Infusional Fluorouracil/Leucovorin (FOLFOX4) for Japanese Patients with Unresectable Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 434-439.	1.3	13
18	Phase II Study of Oral S-1 Plus Irinotecan in Patients with Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 88-89.	1.3	5